DPDIMP#1-trial: Impact of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy
Key facts
- Where
- Helsinki, Oulu és Turku, FinnországSee the 3 sites
- Phase
- 4. fázis
Where in Finnország
- HUS-YhtymaeHelsinki, FinnországNo longer taking part
- Oulu University HospitalOulu, FinnországNo longer taking part
- Turku University HospitalTurku, FinnországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HUS-Yhtymae
- Trial code
- EU 2024-518448-20-00
- Record updated
- 2024. október 29.
- Original description
The aims of this study are to investigate the impact of implementation of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy in Finnish patients and to search for novel genetic variants and other individual characteristics associated with the efficacy and safety of cytostatic therapies.Read full original descriptionShow less
The aims of this study are to investigate the impact of implementation of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy in Finnish patients and to search for novel genetic variants and other individual characteristics associated with the efficacy and safety of cytostatic therapies.
Inclusion: Signed informed consent; Age ≥18 years; Diagnosed breast cancer or colon cancer, which is treated at Helsinki University Central Hospital Cancer Center, in Oulu University Hospital or in Turku University Central Hospital; Planned fluoropyrimidine medication; The result of the DPYD gene test is available before starting fluodopyrimidine medication.
Exclusion: Contraindication to planned fluoropyrimidine medication; Fluoropyrimidine medication as part of chemoradiotherapy; A person referred to in Sections 7-10 of the Medical Research Act (disabled, a minor, pregnant, breastfeeding or a prisoner).